Core Viewpoint - AbCellera Biologics Inc. is recommended as a Buy by Stifel Nicolaus despite reporting a wider-than-expected net loss in Q3 2024, with a price target set at $7 [1][2]. Financial Performance - The company reported a net loss of $57.1 million in Q3 2024, compared to a net loss of $51.1 million in the same quarter last year, indicating a deterioration in financial performance [2]. - Research and development (R&D) expenses increased significantly to $55 million from $41 million year-over-year [2]. - Revenue for the quarter was $9 million, up from $6.5 million in the same quarter last year, showing growth in sales [3]. Operational Highlights - AbCellera achieved key milestones, including the commencement of operations at its new clinical manufacturing facility [3]. - The company is advancing its pipeline with two lead programs, ABCL635 and ABCL575, currently in Phase 1 clinical trials [3][4]. Liquidity Position - The company ended the quarter with approximately $680 million in available liquidity, which will be utilized to execute its strategic plans and advance its clinical studies [4]. Company Overview - AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines using an integrated technology platform [5].